Background: At present there is no clear relationship between DM 2 with respect to lung function decline and even less if the type of treatment would change spirometric variables and inflammatory biomarkers.Objective: To compare the lung function of patients with type 2 diabetes mellitus treated with metformin vs secretagogues and combination with insulin. To Establish the level of inflammatory biomarkers among treatment groups.Methods: Observational study, cross-sectional analytic; 495 diabetic patients between July 2005 and September 2007. Spirometric variables were obtained, levels of inflammatory biomarkers as ferritin, fibrinogen, CRP, Iinterleukina 6, TNF-α. We performed an analysis of residuals of lung function (expected-observed values) between type of treatment with regard to the deterioration in lung function (spirometric variables) and plasma levels of biomarkers.Results: After adjustment for known determinants of lung function, patients treated with metformin had a nonsignificant trend of lower residual FEV1 being of -133.2 (-174.8 ml vs. secretagogue group, P = NS). Like a residual FVC lower in patients treated with metformin compared with secretagogues, being -270.2 -212.1 ml vs. ml respectively (p = 0.039). In the group of patients treated with metformin, inflammatory biomarker levels were lower.Conclusions: This study supports that metformin appears to prevent deterioration of the lung function of patients with diabetes, as seems to have an antiinflammatory effect.
